Management of Coagulopathy in Shock Liver

Pathophysiology and Evidence

• The administration of vitamin K to correct prolonged INR in patients with liver disease lacks supporting evidence, as it does not significantly improve INR 1, 2
• Vitamin K, especially when administered orally or subcutaneously, does not significantly improve INR in patients with liver disease 2

Route of Administration Considerations

• IV vitamin K should be administered slowly to minimize the risk of anaphylactic reactions (3 per 100,000 doses) 3
• Subcutaneous administration is not recommended as it does not modify coagulation parameters effectively 1

Alternative Management Approaches

• Fresh frozen plasma (FFP) may be considered for active bleeding, though only a minority (14%) of patients with liver disease achieve complete INR correction with FFP 1
• FFP transfusion carries potential risks including transfusion-associated circulatory overload and rare transfusion reactions 1

Special Considerations

• Elevated INR in liver disease reflects complex hemostatic changes that are not accurately represented by standard coagulation tests 1, 2
• The occurrence of bleeding in patients with liver disease is often not directly related to the degree of coagulation abnormality but rather to other factors such as portal hypertension 1, 2

Common Pitfalls to Avoid

• Overreliance on INR as a predictor of bleeding risk in liver disease, as studies have shown poor correlation between INR values and bleeding events 1, 2
• Using subcutaneous vitamin K, which has been shown to be ineffective in correcting coagulopathy in liver disease 1